The Swiss Franc (CHF) trades lower in most of its major pairs on Friday after the release of a better-than-expected US jobs report supports risk appetite, driving flows away from the safe-haven Franc.
Blogs
Mexican Peso wraps up Friday’s session with gains, though prints weekly losses against the US Dollar
Mexican Peso (MXN) rallies against the US Dollar (USD) during the North American session on Friday, although data from the United States (US) showed the labor market is not as soft as suggested by previously released data during the week.
Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts
<p>BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes At Week 26, 22 weeks after the last dose of BMF-219, the 200 mg cohorts increased the percentage of patients to approximately 40% with durable HbA1c reduction of 1% or more as compared to the [&hel
ROSEN, LEADING INVESTOR COUNSEL, Encourages Expensify, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – EXFY
<p>NEW YORK, Dec. 09, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Expensify, Inc. (NASDAQ: EXFY) pursuant and/or traceable to the Offering Documents issued in connection with the Company’s Initial Public Offe
FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting
<p>A post hoc analysis of patients with higher transfusion burden at baseline showed a larger percentage of patients achieved transfusion independence ≥ 56 days with roxadustat vs. placebo (36.1% vs 11.5%; p=0.047ǂ). Dr. Moshe Mittelman’s presentation was selected for the “2024 Highlights of ASH” SAN FRANCISCO, Dec. 09, 2023 (GLOBE NEWSWIRE)
FTCH INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Farfetch Limited Investors with Substantial Losses Have Opportunity to Lead Case
<p>SAN DIEGO, Dec. 09, 2023 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Farfetch Limited (NYSE: FTCH) securities between March 9, 2023 and August 17, 2023, all dates inclusive (the “Class Period”), have until December 19, 2023 to seek appointment as lead plaintiff of the Farf
USD/CAD Weekly Forecast: Dollar Thrives on Surprising NFP
<p>The Canadian dollar weakened after the Bank of Canada held rates steady at 5%. Oil fell for a seventh week due to concerns about oversupply. The US economy reported 199,000 jobs last month, while the unemployment rate fell to 3.7%. There is bullish optimism in the USD/CAD weekly forecast amid a stronger dollar. The bigger-than-expectedR
AUD/USD Weekly Forecast: Employment Boost Sparks Dollar
<p>The dollar got a boost from an upbeat employment report. Australia’s central bank kept interest rates unchanged on Tuesday. Investors are eagerly awaiting the FOMC policy meeting. There is a touch of bearish sentiment in the AUD/USD weekly forecast as the dollar recovers after an upbeat employment report. This recovery could spill into nex
Outside the Box: Here’s how to know if your mutual fund sees ESG investing clearly
<p>Measuring the investment horizon of stock funds. Read Full Story</p> <p>The post <a href="https://forextv.com/market-news/outside-the-box-heres-how-to-know-if-your-mutual-fund-sees-esg-investing-clearly/">Outside the Box: Here’s how to know if your mutual fund sees ESG investing clearly</a> appeared first
Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)
<p>Rapid and ongoing improvement in patient symptoms, with 57% median best improvement on MC-QoL and 78% of patients reporting ≥1 point improvement on PGIS by week 20 100% of bezuclastinib treated patients achieved at least 50% improvement across all relevant biomarker measures, including serum tryptase, KIT D816V VAF, and mast cell burden; P